Lauren Rusckowski Duprey

CIK: 0001977746

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TAK

TAKEDA PHARMACEUTICAL CO LTD

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

TAK
TAKEDA PHARMACEUTICAL CO LTD
Sep 14, 2026
Sale(S)
Direct
34.5K shares at avg. $18.54$640K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 10, 2026
Sale(S)
Direct
47.6K shares at avg. $17.10$814K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Jul 1, 2026
Award(A)
Direct
45.1K shares-
TAK
TAKEDA PHARMACEUTICAL CO LTD
Apr 27, 2026
Award(A)
Direct
60K shares-

		Type	Shares	Price		Ownership
Sep 14, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	34,535	$18.54	$640,279	Direct
Aug 10, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	47,586	$17.10	$813,721	Direct
Jul 1, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	45,140	-	$0	Direct
Apr 27, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	59,990	-	$0	Direct

1-4 of 4 transactions

About Duprey Lauren Rusckowski

Duprey Lauren Rusckowski (SEC CIK 0001977746) files insider reports with the SEC as Chief Transformation Officer of TAKEDA PHARMACEUTICAL CO LTD (TAK).

Signal8 holds 5 ownership filings by Duprey Lauren Rusckowski (1 Form 3, 4 Form 4), filed between Mar 18, 2026 and Sep 15, 2026. Those filings report 4 transactions, from Apr 27, 2026 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Duprey Lauren Rusckowski's filings is in LEXINGTON, MA.

Recent filings by Duprey Lauren Rusckowski

Sep 14, 2026: Open-market sale of TAK shares (Form 4, code S).
Aug 10, 2026: Open-market sale of TAK shares (Form 4, code S).
Jul 1, 2026: Grant or award of TAK shares (Form 4, code A).
Apr 27, 2026: Grant or award of TAK shares (Form 4, code A).

Other insiders filing for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Plump Andrew Stewart, President, R&D
Greenway Nicola Deidre Petal, Chief Human Resources Officer
Farajallah Awny Samaan Botros, Chief Medical Officer
Ibrahim Ramy Riad Ahmed, President, PDT BU
Pacheco Rhonda Janice, President, U.S. Business Unit
Pignagnoli Agosti Marcello, Head, Strat. & Port. Dev

How to read Form 4 transaction codes